Please login to the form below

Not currently logged in
Email:
Password:

Roche and Evotec form biomarker alliance

Roche and Evotec are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development

Roche and Evotec, a drug discovery company specialising in development partnerships, are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development.

Evotec will employ its PhosphoScout platform to discover protein-phosphorylation's that predict favourable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials, as well as assessing the development of companion diagnostics for patient stratification.

Mike Burgess, global head of oncology at Roche Pharma Research and Exploratory Development, said: "We are very pleased to collaborate with Evotec and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers. They are core to the development of targeted therapeutics for cancer therapy."

Under the initial three-year term Roche and Evotec will conduct multiple biomarker programmes for therapeutic antibodies or small molecule inhibitors.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics